Discoid lupus erythematosus successfully treated with deucravacitinib

Abstract

Discoid lupus erythematosus (DLE) is a scarring form of cutaneous lupus erythematosus (CLE) characterized by inflammation, dyspigmentation, and alopecia. Given the degree of disfigurement it causes, there is significant negative impact on quality of life. Management of DLE has largely consisted of antimalarials and topical/intralesional corticosteroids. Mycophenolate mofetil, methotrexate, and thalidomide/lenalidomide have been utilized as second and/or third line agents with more recent studies supporting the use of anifrolumab in recalcitrant DLE cases.

Topics & Concepts